Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-13
Publisher
Informa UK Limited
Online
2020-06-16
DOI
10.1080/14656566.2020.1774553
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
- (2020) Vlad Ratziu et al. HEPATOLOGY
- Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
- (2020) Sander Lefere et al. JOURNAL OF HEPATOLOGY
- The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis
- (2020) Tobias Puengel et al. Journal of Clinical Medicine
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients with Chronic Hepatitis C after Viral Eradication
- (2019) Sheng-Hung Chen et al. CLINICAL INFECTIOUS DISEASES
- Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores
- (2019) George N. Ioannou et al. GASTROENTEROLOGY
- Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
- (2019) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials
- (2019) Iram Amanullah et al. POSTGRADUATE MEDICAL JOURNAL
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
- (2019) Rohit A. Sinha et al. THYROID
- The FGF metabolic axis
- (2019) Xiaokun Li Frontiers of Medicine
- Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy
- (2019) Rui Huang et al. DIGESTIVE DISEASES AND SCIENCES
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Serelaxin inhibits the profibrotic TGF-β1/IL-1β axis by targeting TLR-4 and the NLRP3 inflammasome in cardiac myofibroblasts
- (2019) Felipe Tapia Cáceres et al. FASEB JOURNAL
- New drugs for NAFLD: lessons from basic models to the clinic
- (2019) Katharina C. Reimer et al. Hepatology International
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
- (2019) Ying Lu et al. PeerJ
- Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
- (2019) Joost Boeckmans et al. Cells
- Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis
- (2018) David H Ipsen et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Prospects in non-invasive assessment of liver fibrosis: Liquid biopsy as the future gold standard?
- (2018) Joeri Lambrecht et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Management of decompensated cirrhosis
- (2018) Dina Mansour et al. CLINICAL MEDICINE
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- Lipotoxicity and the gut-liver axis in NASH pathogenesis
- (2018) Fabio Marra et al. JOURNAL OF HEPATOLOGY
- Genetics and epigenetics of NAFLD and NASH: Clinical impact
- (2018) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
- (2018) Chris Estes et al. JOURNAL OF HEPATOLOGY
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
- (2018) Sorim Choung et al. PPAR Research
- Activation of the Immune-Metabolic Receptor GPR84 Enhances Inflammation and Phagocytosis in Macrophages
- (2018) Carlota Recio et al. Frontiers in Immunology
- Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
- (2018) Maurizio Parola et al. MOLECULAR ASPECTS OF MEDICINE
- Apoptosis and necroptosis in the liver: a matter of life and death
- (2018) Robert F. Schwabe et al. Nature Reviews Gastroenterology & Hepatology
- Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease
- (2018) Mitchell Shiffman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
- (2018) Rohit Loomba et al. GASTROENTEROLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
- (2018) Yuya Seko et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Effect of GPR84 deletion on obesity and diabetes development in mice fed long chain or medium chain fatty acid rich diets
- (2017) Eugene Du Toit et al. EUROPEAN JOURNAL OF NUTRITION
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- The origin of fibrogenic myofibroblasts in fibrotic liver
- (2017) Tatiana Kisseleva HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
- (2017) Yong-ho Lee et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- Mechanisms of hepatic stellate cell activation
- (2017) Takuma Tsuchida et al. Nature Reviews Gastroenterology & Hepatology
- Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis
- (2017) Robert G Bennett et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe?
- (2016) Bin Gao et al. GASTROENTEROLOGY
- Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells
- (2016) Yumin Oh et al. HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
- (2016) Elena Buzzetti et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats
- (2016) Geraldine Harriman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pioglitazone use and risk of bladder cancer: population based cohort study
- (2016) Marco Tuccori et al. BMJ-British Medical Journal
- Pioglitazone use and risk of bladder cancer: population based cohort study
- (2016) Marco Tuccori et al. BMJ-British Medical Journal
- PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
- (2016) Xiaomeng Feng et al. MEDICAL SCIENCE MONITOR
- Statins Increase Mitochondrial and Peroxisomal Fatty Acid Oxidation in the Liver and Prevent Non-Alcoholic Steatohepatitis in Mice
- (2016) Han-Sol Park et al. Diabetes & Metabolism Journal
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
- (2015) Guillaume Lassailly et al. GASTROENTEROLOGY
- Pathobiology of liver fibrosis: a translational success story
- (2015) Youngmin A Lee et al. GUT
- Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
- (2015) Tadashi Namisaki et al. JOURNAL OF GASTROENTEROLOGY
- Hepatic fibrosis: Concept to treatment
- (2015) Christian Trautwein et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Tumor necrosis factor–related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype
- (2015) Jing Gao et al. MOLECULAR BIOLOGY OF THE CELL
- The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
- (2014) Rifaat Safadi et al. Clinical Gastroenterology and Hepatology
- Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
- (2014) Tom Luedde et al. GASTROENTEROLOGY
- Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis
- (2014) Chris J. Weston et al. JOURNAL OF CLINICAL INVESTIGATION
- Biomarkers of liver cell death
- (2014) Akiko Eguchi et al. JOURNAL OF HEPATOLOGY
- Macrophage heterogeneity in liver injury and fibrosis
- (2014) Frank Tacke et al. JOURNAL OF HEPATOLOGY
- The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
- (2014) Fernando J. Barreyro et al. LIVER INTERNATIONAL
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats
- (2012) Aina Rodríguez-Vilarrupla et al. JOURNAL OF HEPATOLOGY
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Rafael Lozano et al. LANCET
- A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis
- (2011) Vlad Ratziu et al. HEPATOLOGY
- High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial
- (2010) Ulrich F. H. Leuschner et al. HEPATOLOGY
- Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH
- (2010) Yuki Kimura et al. JOURNAL OF GASTROENTEROLOGY
- New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis
- (2010) Yan Wang et al. JOURNAL OF HEPATOLOGY
- Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis
- (2010) Quentin M. Anstee et al. JOURNAL OF HEPATOLOGY
- Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3 in liver
- (2010) Carla Iacobini et al. JOURNAL OF HEPATOLOGY
- Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment
- (2010) Vivian Barry-Hamilton et al. NATURE MEDICINE
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Harmonizing the Metabolic Syndrome
- (2009) K.G.M.M. Alberti et al. CIRCULATION
- CCR2 promotes hepatic fibrosis in mice
- (2009) Ekihiro Seki et al. HEPATOLOGY
- Bile acids: regulation of apoptosis by ursodeoxycholic acid
- (2009) Joana D. Amaral et al. JOURNAL OF LIPID RESEARCH
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
- Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
- (2008) Vlad Ratziu et al. GASTROENTEROLOGY
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
- Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist
- (2008) Edward E. Cable et al. HEPATOLOGY
- Liver cirrhosis
- (2008) Detlef Schuppan et al. LANCET
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now